SEATTLE — The phase 2 AAVIATE study showed safety and efficacy of ABBV-RGX-314 gene therapy in the treatment of neovascular age-related macular degeneration, with potential for sustained outcomes with a one-time in-office injection.
Five groups of patients previously treated with anti-VEGF were administered the therapy in three different doses via suprachoroidal injection; in cohorts 1 and 2, ABBV-RGX-314 (Regenxbio/AbbVie) was compared with monthly ranibizumab intravitreal injection. An additional group, cohort 6, received ABBV-RGX-314 with a short course of topical steroids or one-time